AU2016297608B2 - Methods of preparing cytotoxic benzodiazepine derivatives - Google Patents

Methods of preparing cytotoxic benzodiazepine derivatives Download PDF

Info

Publication number
AU2016297608B2
AU2016297608B2 AU2016297608A AU2016297608A AU2016297608B2 AU 2016297608 B2 AU2016297608 B2 AU 2016297608B2 AU 2016297608 A AU2016297608 A AU 2016297608A AU 2016297608 A AU2016297608 A AU 2016297608A AU 2016297608 B2 AU2016297608 B2 AU 2016297608B2
Authority
AU
Australia
Prior art keywords
formula
compound
meo
ome
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016297608A
Other languages
English (en)
Other versions
AU2016297608A1 (en
Inventor
Baudouin GÉRARD
Michael Louis Miller
Manami Shizuka
Richard A. Silva
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of AU2016297608A1 publication Critical patent/AU2016297608A1/en
Application granted granted Critical
Publication of AU2016297608B2 publication Critical patent/AU2016297608B2/en
Priority to AU2021202403A priority Critical patent/AU2021202403B2/en
Priority to AU2023201339A priority patent/AU2023201339A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016297608A 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives Ceased AU2016297608B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021202403A AU2021202403B2 (en) 2015-07-21 2021-04-20 Methods of preparing cytotoxic benzodiazepine derivatives
AU2023201339A AU2023201339A1 (en) 2015-07-21 2023-03-03 Methods of preparing cytotoxic benzodiazepine derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195023P 2015-07-21 2015-07-21
US62/195,023 2015-07-21
US201662327973P 2016-04-26 2016-04-26
US62/327,973 2016-04-26
PCT/US2016/043406 WO2017015496A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202403A Division AU2021202403B2 (en) 2015-07-21 2021-04-20 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (2)

Publication Number Publication Date
AU2016297608A1 AU2016297608A1 (en) 2018-02-08
AU2016297608B2 true AU2016297608B2 (en) 2021-02-18

Family

ID=56557925

Family Applications (7)

Application Number Title Priority Date Filing Date
AU2016297608A Ceased AU2016297608B2 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
AU2016297087A Ceased AU2016297087B2 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
AU2016297607A Abandoned AU2016297607A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
AU2021202403A Ceased AU2021202403B2 (en) 2015-07-21 2021-04-20 Methods of preparing cytotoxic benzodiazepine derivatives
AU2021203148A Ceased AU2021203148B2 (en) 2015-07-21 2021-05-17 Methods of preparing cytotoxic benzodiazepine derivatives
AU2023201339A Abandoned AU2023201339A1 (en) 2015-07-21 2023-03-03 Methods of preparing cytotoxic benzodiazepine derivatives
AU2023202221A Abandoned AU2023202221A1 (en) 2015-07-21 2023-04-11 Methods of preparing cytotoxic benzodiazepine derivatives

Family Applications After (6)

Application Number Title Priority Date Filing Date
AU2016297087A Ceased AU2016297087B2 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
AU2016297607A Abandoned AU2016297607A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
AU2021202403A Ceased AU2021202403B2 (en) 2015-07-21 2021-04-20 Methods of preparing cytotoxic benzodiazepine derivatives
AU2021203148A Ceased AU2021203148B2 (en) 2015-07-21 2021-05-17 Methods of preparing cytotoxic benzodiazepine derivatives
AU2023201339A Abandoned AU2023201339A1 (en) 2015-07-21 2023-03-03 Methods of preparing cytotoxic benzodiazepine derivatives
AU2023202221A Abandoned AU2023202221A1 (en) 2015-07-21 2023-04-11 Methods of preparing cytotoxic benzodiazepine derivatives

Country Status (23)

Country Link
US (11) US9890179B2 (enExample)
EP (7) EP3325482B1 (enExample)
JP (8) JP2018522018A (enExample)
KR (5) KR20240055894A (enExample)
CN (5) CN108290895B (enExample)
AU (7) AU2016297608B2 (enExample)
CA (4) CA2991305C (enExample)
CY (2) CY1122553T1 (enExample)
DK (2) DK3325483T3 (enExample)
ES (4) ES2764548T3 (enExample)
HK (1) HK1252322A1 (enExample)
HR (1) HRP20201479T1 (enExample)
HU (1) HUE051541T2 (enExample)
IL (10) IL305279A (enExample)
LT (2) LT3325482T (enExample)
PL (2) PL3325483T3 (enExample)
PT (2) PT3325483T (enExample)
RS (2) RS60840B1 (enExample)
RU (3) RU2018105752A (enExample)
SG (2) SG10202106529XA (enExample)
SI (2) SI3325482T1 (enExample)
SM (2) SMT202000004T1 (enExample)
WO (3) WO2017015496A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000004T1 (it) 2015-07-21 2020-03-13 Immunogen Inc Metodi di preparazione dei derivati citotossici di benzodiazepina
KR20250008963A (ko) 2016-03-22 2025-01-16 에베 그룹 에. 탈너 게엠베하 기판을 결합하기 위한 방법 및 장치
IL326918A (en) 2016-10-19 2026-05-01 Invenra Inc Antibody structures
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
PL3573948T3 (pl) 2017-01-25 2023-01-30 Immunogen, Inc. Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
CA3119358A1 (en) 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
WO2020102053A1 (en) * 2018-11-12 2020-05-22 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
EP3947395A1 (en) * 2019-03-29 2022-02-09 ImmunoGen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
PT1109812E (pt) 1998-08-27 2005-09-30 Spirogen Ltd Pirrolobenzodiazepinas
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
KR20050032110A (ko) 2002-08-02 2005-04-06 이뮤노젠 아이엔씨 신규의 효능을 갖는 탁산을 포함하는 세포독성제 및 그치료용도
ES2361739T3 (es) 2002-08-16 2011-06-21 Immunogen, Inc. Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña.
EP1608664B1 (en) 2003-03-31 2009-01-28 Council of Scientific and Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EP1608663B1 (en) 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
RU2314309C2 (ru) 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ATE516288T1 (de) 2003-10-22 2011-07-15 Us Gov Health & Human Serv Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
JP4520411B2 (ja) 2003-12-31 2010-08-04 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン・ハイブリッドの調製方法
CA2558195C (en) * 2004-03-01 2012-11-06 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) * 2004-06-04 2004-07-07 Sterix Ltd Compound
EP1879901B1 (en) 2005-04-21 2009-12-23 Spirogen Limited Pyrrolobenzodiazepines
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
ATE427949T1 (de) 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
CN102702194A (zh) * 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
JP2009526778A (ja) 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
WO2007140371A2 (en) 2006-05-30 2007-12-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
WO2009016647A1 (en) 2007-08-01 2009-02-05 Council Of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
RU2487877C2 (ru) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры)
EP2281006B1 (en) 2008-04-30 2017-08-02 Immunogen, Inc. Cross-linkers and their uses
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0822260D0 (en) 2008-12-05 2009-01-14 Merten Christoph Assay
KR101172638B1 (ko) * 2008-12-30 2012-08-08 조선대학교산학협력단 신규한 티아졸리딘디온 유도체 및 그의 용도
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
JP2013506709A (ja) 2009-10-06 2013-02-28 イミュノジェン・インコーポレーテッド 有効なコンジュゲートおよび親水性リンカー
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
CN102666480B (zh) 2009-12-08 2014-04-09 国立大学法人岐阜大学 芳香族化合物、低聚核苷酸衍生物合成用修饰载体、低聚核苷酸衍生物及低聚核苷酸构建物
US8962279B2 (en) * 2009-12-30 2015-02-24 Intel Corporation Solid-phase chelators and electronic biosensors
SG10201501062SA (en) * 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
KR20140010076A (ko) * 2011-02-15 2014-01-23 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
HK1211208A1 (zh) * 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
KR102298475B1 (ko) * 2013-10-04 2021-09-06 노파르티스 아게 ＲＮＡ 간섭에 사용하기 위한 ＲＮＡｉ 작용제를 위한 3' 말단 캡
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) * 2013-11-25 2016-03-02 济南精合医药科技有限公司 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
PT3189056T (pt) 2014-09-03 2020-09-04 Immunogen Inc Derivados citotóxicos de benzodiazepina
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
SMT202000004T1 (it) 2015-07-21 2020-03-13 Immunogen Inc Metodi di preparazione dei derivati citotossici di benzodiazepina
US20170189548A1 (en) * 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof

Also Published As

Publication number Publication date
US20170050985A1 (en) 2017-02-23
EP3325485A1 (en) 2018-05-30
AU2016297087A1 (en) 2018-02-08
US20170050986A1 (en) 2017-02-23
US10081640B2 (en) 2018-09-25
ES2933376T3 (es) 2023-02-06
IL276631A (en) 2020-09-30
IL294651B2 (en) 2024-02-01
IL283355B (en) 2022-08-01
US20170051011A1 (en) 2017-02-23
HK1252322A1 (zh) 2019-05-24
CN108026103A (zh) 2018-05-11
HRP20201479T1 (hr) 2020-12-11
ES2820358T3 (es) 2021-04-20
IL276630B (en) 2021-06-30
JP2021100959A (ja) 2021-07-08
CA3227588A1 (en) 2017-01-26
IL286788B2 (en) 2024-01-01
PL3325482T3 (pl) 2021-01-11
PL3325483T3 (pl) 2020-05-18
US20210171547A1 (en) 2021-06-10
JP7334228B2 (ja) 2023-08-28
IL276631B (en) 2021-10-31
CN108026103B (zh) 2021-04-16
IL305989A (en) 2023-11-01
US20190010169A1 (en) 2019-01-10
EP3325482A1 (en) 2018-05-30
CA2991305A1 (en) 2017-01-26
KR20180038460A (ko) 2018-04-16
CA2991305C (en) 2024-03-12
CN108055844A (zh) 2018-05-18
CN113087763A (zh) 2021-07-09
RU2018105752A3 (enExample) 2019-12-30
WO2017015502A8 (en) 2017-03-02
HK1252323A1 (en) 2019-05-24
JP6787995B2 (ja) 2020-11-18
IL256854A (en) 2018-03-29
JP6995178B2 (ja) 2022-02-21
IL256861A (en) 2018-03-29
EP4163284A1 (en) 2023-04-12
EP3325482B1 (en) 2020-06-24
US20190389883A1 (en) 2019-12-26
CY1122553T1 (el) 2021-01-27
SMT202000506T1 (it) 2020-11-10
IL283355A (en) 2021-07-29
US10899775B2 (en) 2021-01-26
LT3325483T (lt) 2020-01-27
ES2959741T3 (es) 2024-02-28
RS59806B1 (sr) 2020-02-28
AU2016297607A1 (en) 2018-02-08
SG10202106529XA (en) 2021-07-29
EP3778602B1 (en) 2023-07-12
EP3778602A1 (en) 2021-02-17
US20200017526A1 (en) 2020-01-16
KR102659706B1 (ko) 2024-04-23
CN108290895A (zh) 2018-07-17
WO2017015496A1 (en) 2017-01-26
JP2021035958A (ja) 2021-03-04
PT3325482T (pt) 2020-09-24
KR20180026741A (ko) 2018-03-13
PT3325483T (pt) 2020-01-15
US20230257400A1 (en) 2023-08-17
US10392407B2 (en) 2019-08-27
KR20180038461A (ko) 2018-04-16
KR102660070B1 (ko) 2024-04-24
RU2018105609A3 (enExample) 2020-04-30
US20210171546A1 (en) 2021-06-10
AU2021202403A1 (en) 2021-05-20
US20190112320A1 (en) 2019-04-18
EP3653628A1 (en) 2020-05-20
RU2018105756A3 (enExample) 2019-12-23
EP4286387A2 (en) 2023-12-06
KR20240055894A (ko) 2024-04-29
SMT202000004T1 (it) 2020-03-13
CA2991326A1 (en) 2017-01-26
US9873708B2 (en) 2018-01-23
IL286788B1 (en) 2023-09-01
EP4286387A3 (en) 2024-02-21
IL294651A (en) 2022-09-01
US20180201626A1 (en) 2018-07-19
EP3325485B1 (en) 2020-04-08
JP2018526340A (ja) 2018-09-13
JP2018524387A (ja) 2018-08-30
JP2023162264A (ja) 2023-11-08
SI3325483T1 (sl) 2020-03-31
EP3325483A1 (en) 2018-05-30
DK3325483T3 (da) 2020-01-20
CY1123390T1 (el) 2022-03-24
HK1252321A1 (en) 2019-05-24
IL294651B1 (en) 2023-10-01
CA2992082A1 (en) 2017-01-26
RU2018105756A (ru) 2019-08-21
RS60840B1 (sr) 2020-10-30
WO2017015502A1 (en) 2017-01-26
RU2746322C2 (ru) 2021-04-12
LT3325482T (lt) 2020-11-25
AU2016297087B2 (en) 2021-02-18
ES2764548T3 (es) 2020-06-03
US9890179B2 (en) 2018-02-13
AU2023202221A1 (en) 2023-05-04
WO2017015495A1 (en) 2017-01-26
AU2021203148B2 (en) 2023-01-12
SI3325482T1 (sl) 2020-11-30
IL256860A (en) 2018-03-29
IL305279A (en) 2023-10-01
SG10202009354SA (en) 2020-11-27
DK3325482T3 (da) 2020-09-28
RU2018105752A (ru) 2019-08-21
IL256861B (en) 2020-08-31
US10787463B2 (en) 2020-09-29
JP2023166434A (ja) 2023-11-21
EP3325483B1 (en) 2019-10-02
US10370389B2 (en) 2019-08-06
IL286788A (en) 2021-10-31
AU2023201339A1 (en) 2023-04-06
US11420982B2 (en) 2022-08-23
JP2018522018A (ja) 2018-08-09
CN113004288A (zh) 2021-06-22
IL256860B (en) 2020-08-31
KR20240055903A (ko) 2024-04-29
AU2021203148A1 (en) 2021-06-10
CN108290895B (zh) 2021-03-19
IL276630A (en) 2020-09-30
JP7337114B2 (ja) 2023-09-01
RU2727151C2 (ru) 2020-07-21
JP6858745B2 (ja) 2021-04-14
RU2018105609A (ru) 2019-08-26
AU2021202403B2 (en) 2022-12-08
JP2022046542A (ja) 2022-03-23
AU2016297608A1 (en) 2018-02-08
EP3653628B1 (en) 2022-09-14
HUE051541T2 (hu) 2021-03-01

Similar Documents

Publication Publication Date Title
AU2021202403B2 (en) Methods of preparing cytotoxic benzodiazepine derivatives
AU2024201119A1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40088821A (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40029973A (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40029973B (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK1252323B (en) Methods of preparing cytotoxic benzodiazepine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired